141 related articles for article (PubMed ID: 22271880)
1. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Gilbert J; Rudek MA; Higgins MJ; Zhao M; Bienvenu S; Tsottles N; Chaudhry MA; Wahl R; Forastiere A; Gillison M
Clin Cancer Res; 2012 Mar; 18(6):1735-42. PubMed ID: 22271880
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: a GICOR phase I trial.
Arias de la Vega F; Contreras J; de Las Heras M; de la Torre A; Arrazubi V; Herruzo I; Prieto I; García-Saenz JA; Romero J; Calvo FA;
Ann Oncol; 2012 Apr; 23(4):1005-9. PubMed ID: 21778302
[TBL] [Abstract][Full Text] [Related]
3. Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Ahn PH; Machtay M; Anne PR; Cognetti D; Keane WM; Wuthrick E; Dicker AP; Axelrod RS
Am J Clin Oncol; 2018 May; 41(5):441-446. PubMed ID: 27391356
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study.
Siu LL; Soulieres D; Chen EX; Pond GR; Chin SF; Francis P; Harvey L; Klein M; Zhang W; Dancey J; Eisenhauer EA; Winquist E; ;
J Clin Oncol; 2007 Jun; 25(16):2178-83. PubMed ID: 17538162
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial.
Martins RG; Parvathaneni U; Bauman JE; Sharma AK; Raez LE; Papagikos MA; Yunus F; Kurland BF; Eaton KD; Liao JJ; Mendez E; Futran N; Wang DX; Chai X; Wallace SG; Austin M; Schmidt R; Hayes DN
J Clin Oncol; 2013 Apr; 31(11):1415-21. PubMed ID: 23460709
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer.
Rao K; Kalapurakal S; Chalasani P; Robinson K; Malone J; Clausen C; Ronen O; Dhiwakar M; Shevlin B; Robbins KT
Cancer Chemother Pharmacol; 2013 Sep; 72(3):545-52. PubMed ID: 23884559
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.
Papadimitrakopoulou VA; Frank SJ; Cohen EW; Hirsch FR; Myers JN; Heymach JV; Lin H; Tran HT; Chen CR; Jimeno A; Nedzi L; Vasselli JR; Lowe ES; Raben D
Head Neck; 2016 Mar; 38(3):439-47. PubMed ID: 25352401
[TBL] [Abstract][Full Text] [Related]
8. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma.
Galloway TJ; Wirth LJ; Colevas AD; Gilbert J; Bauman JE; Saba NF; Raben D; Mehra R; Ma AW; Atoyan R; Wang J; Burtness B; Jimeno A
Clin Cancer Res; 2015 Apr; 21(7):1566-73. PubMed ID: 25573383
[TBL] [Abstract][Full Text] [Related]
11. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
[TBL] [Abstract][Full Text] [Related]
12. Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.
Harrington K; Temam S; Mehanna H; D'Cruz A; Jain M; D'Onofrio I; Manikhas G; Horvath Z; Sun Y; Dietzsch S; Dubinsky P; Holeckova P; El-Hariry I; Franklin N; Biswas-Baldwin N; Legenne P; Wissel P; Netherway T; Farrell J; Ellis C; Wang-Silvanto J; Amonkar M; Ahmed N; Santillana S; Bourhis J
J Clin Oncol; 2015 Dec; 33(35):4202-9. PubMed ID: 26527790
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer.
Allal AS; Zwahlen D; Becker M; Dulguerov P; Mach N
Cancer J; 2006; 12(1):63-8. PubMed ID: 16613664
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
Dobelbower MC; Russo SM; Raisch KP; Seay LL; Clemons LK; Suter S; Posey J; Bonner JA
Anticancer Drugs; 2006 Jan; 17(1):95-102. PubMed ID: 16317296
[TBL] [Abstract][Full Text] [Related]
16. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of chemoradiotherapy with the combination of S-1 plus cisplatin for patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Tahara M; Minami H; Kawashima M; Kawada K; Mukai H; Sakuraba M; Matsuura K; Ogino T; Hayashi R; Ohtsu A
Cancer Sci; 2011 Feb; 102(2):419-24. PubMed ID: 21134076
[TBL] [Abstract][Full Text] [Related]
19. Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.
Harrington K; Berrier A; Robinson M; Remenar E; Housset M; de Mendoza FH; Fayette J; Mehanna H; El-Hariry I; Compton N; Franklin N; Biswas-Baldwin N; Lau M; Legenne P; Kumar R
Eur J Cancer; 2013 May; 49(7):1609-18. PubMed ID: 23265705
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Yao M; Woods C; Lavertu P; Fu P; Gibson M; Rezaee R; Zender C; Wasman J; Sharma N; Machtay M; Savvides P
Head Neck; 2016 Apr; 38 Suppl 1(Suppl 1):E1770-6. PubMed ID: 26918562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
